We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves Novartis’ Signifor LAR to Treat Acromegaly
FDA Approves Novartis’ Signifor LAR to Treat Acromegaly
The FDA has approved Swiss drugmaker Novartis’ long-acting-release form of Signifor to treat the rare and life-threatening hormonal disorder acromegaly, following its approval in Europe last month.